Sflt-1 in heart failure: relation with disease severity and biomarkers. (3rd July 2016)

• Record Type: Journal Article
• Authors: Gruson, Damien; Hermans, Michel P.; Ferracin, Benjamin; Ahn, Sylvie A.; Rousseau, Michel F.
• Is Part Of: Scandinavian journal of clinical & laboratory investigation. Volume 76:Number 5(2016)
• Page Start: 411
• Page End: 416
• Publication Date: 2016-07-03
• Subjects: Aldosterone -- BNP -- Galectin-3 -- heart failure -- prognosis sFlt-1 -- ST2; Clinical biochemistry -- Periodicals; Physiology, Pathological -- Periodicals; Physiology, Experimental -- Periodicals; Medicine -- Research -- Periodicals; Clinical medicine -- Periodicals; 616.0072
• DOI: 10.1080/00365513.2016.1190863
• Languages: English
• ISSNs: 0036-5513

Abstract

Abstract: Soluble fms-like tyrosine kinase-1 (sFlt-1) is an endogenous inhibitor of endothelial growth factors, such as placental growth factor (PlGF), which modulates cardiovascular (CV) remodeling. We determine sFlt-1 levels in patients with heart failure (HF) and its relationship to adverse cardiovascular (CV) events and biomarkers of cardiovascular risk. Levels of sFlt-1 and PlGF levels were also determined in healthy volunteers and patients with type 2 diabetes mellitus (T2DM). SFlt-1 and PlGF were clearly increased in HF patients in comparison to T2DM patients or healthy subjects ( p < 0.01). Concentration of sFlt-1 was related to HF severity ( p < 0.001) and was correlated to NT-proBNP ( ρ = 0.37, p < 0.01), soluble ST2 ( ρ = 0.52, p < 0.01), Galectin-3 ( ρ = 0.38, p < 0.01), aldosterone ( ρ = 0.25, p = 0.01) and PTH(1–84) ( ρ = 0.38, p < 0.01). Furthermore, sFlt-1 levels were associated to long-term CV risk. These results suggest a potential role of sFlt-1 in HF and its potential role as biomarker of CV risk.